Page results
-
Information about the Integrated General Medicine Service at the RLHIM patient information leaflet.
-
To mark International Brain Tumour Awareness Week, UCLH and The National Brain Appeal are announcing a new clinical trial for patients with recurrent glioblastoma brain cancer.
-
This page explains what FACETS is and how it can help you.
-
Three patients in the UK have received an innovative treatment for the most serious form of lupus – an autoimmune condition which can cause damage to the heart, lungs, joints, brain or kidneys.
-
This page provides information about achalasia and its diagnosis and treatment.
-
This page is aimed at providing guidance and recommendations for patients, carers or family members following a high dose examination or procedure performed in the Neuroradiology department at NHNN, which involved ionising radiation.
-
This page has been written for patients who have been referred for High Dose Rate (HDR) brachytherapy to the bronchus
-
UCLH is the first NHS centre in the UK to offer patients suffering from obstructive sleep apnœa (OSA) a choice of nerve stimulation devices to manage their condition.
-
This information has been written for patients who have been referred for High Dose Rate (HDR) brachytherapy to the oesophagus (gullet).
-
This page provides information about post procedural care following a diagnostic angiogram or endovascular treatment and possible complications that may occur.
File results
-
FOI/2023/0670 - Treatment with immunomodulatory medications
-
FOI/2023/0672 - Treatment with dermatology and respiratory medicine
-
FOI/2023/0675 - Number of cancer treatments at each stage
-
FOI/2023/0681 - Patient friends and family test supplier
-
FOI/2023/0683 - Electronic Patient Records (EPR)/ Patient Administration System (PAS)
-
FOI/2023/0686 - Hysteroscopy Inpatient and Outpatient pathways
-
FOI/2023/0687 - Information Governance pay grades
-
FOI/2023/0689 - Access to digital test results for patients
-
FOI/2023/0691 - Integrated medicine
-
FOI/2023/0692 - Trust's Five year strategy spend